Register Login
Register to leave comments
  • News bot May 4, 2026, 8:35 p.m.

    📋 MARKER THERAPEUTICS, INC. (MRKR) - Regulatory Update

    Filing Date: 2026-05-04

    Accepted: 2026-05-04 16:30:23

    Event Type: Regulatory Update

    Event Details:

    MARKER THERAPEUTICS, INC. (MRKR) Announces Regulatory Update MARKER THERAPEUTICS, INC. (MRKR) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (MARKER THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Blood draw at Days 0, 7, 14, and 21 Other Preclinical Brain Injuries, Traumatic ClinicalTrials.gov
    Standard of care Other Phase PHASE2 Acute Ischemic Stroke ClinicalTrials.gov
    Medical oxygen Other Phase PHASE2 Acute Ischemic Stroke ClinicalTrials.gov
    Prognostic value of Biomarkers Other Preclinical Severe Dyspnea ClinicalTrials.gov
    Copeptin Other Approved Chest Pain ClinicalTrials.gov
    Biomarkers, red blood cells and plasma assessment Other Approved Cerebral Hemorrhage ClinicalTrials.gov
    AECOPD Mr proADM Other Approved Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation ClinicalTrials.gov
    Subject's usual brand (UB) tobacco product Other Preclinical Cardiovascular Disease ClinicalTrials.gov
    Banyan Biomarkers Other Preclinical Traumatic Brain Injury ClinicalTrials.gov
    48 hours of therapeutic hypothermia Other Approved Cardiac Arrest ClinicalTrials.gov
    Blood draw within 12 hours of injury Other Preclinical Traumatic Brain Injury ClinicalTrials.gov
    NT-Pro BNP Other Approved Heart Failure ClinicalTrials.gov
    laboratory biomarker analysis Other Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    HER-2/neu peptide vaccine Other Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    Skin care Other Approved Atopic Dermatitis ClinicalTrials.gov
    Food intervention Other Approved Atopic Dermatitis ClinicalTrials.gov
    Blood draw Other Preclinical Traumatic Brain Injury ClinicalTrials.gov
    Head CT scan and blood draw within 12 hours of injury Other Preclinical Traumatic Brain Injury ClinicalTrials.gov
    Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System Other Preclinical Schizophrenia ClinicalTrials.gov
    ARNA Breast Other Preclinical Breast Neoplasms ClinicalTrials.gov
    Blood sampling for MR-proADM & CT-proET-1 Other Preclinical Acute Phase Biomarkers ClinicalTrials.gov
    High dose FRα vaccine Other Phase PHASE2 Breast Cancer ClinicalTrials.gov
    Cyclophosphamide Other Phase PHASE2 Breast Cancer ClinicalTrials.gov
    Low dose FRα vaccine Other Phase PHASE2 Breast Cancer ClinicalTrials.gov
    Durvalumab Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    TPIV200 Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) Other Approved Respiratory Failure ClinicalTrials.gov
    WM-S1-030 Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Observational Study Other Preclinical Electrolyte Imbalances ClinicalTrials.gov
    Adjuvant (GM-CSF) Alone Other Phase PHASE2 Platinum Sensitive Ovarian Cancer ClinicalTrials.gov
    FRα peptide plus Adjuvant (GM-CSF) Other Phase PHASE2 Platinum Sensitive Ovarian Cancer ClinicalTrials.gov
    Cell-based non-invasive prenatal testing Other Approved Prenatal Screening ClinicalTrials.gov
    Ketamine Other Phase EARLY_PHASE1 Healthy ClinicalTrials.gov
    Pembrolizumab Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    WM-A1-3389 Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    MT-601 Other Phase PHASE1 Pancreas Cancer ClinicalTrials.gov
    Altoida: neuropsychological, MRI, EEG and CSF biomarkers Other Approved Alzheimer Disease ClinicalTrials.gov
    colonoscopy Other Approved Colorectal Cancer Screening ClinicalTrials.gov
    stool sampling Other Approved Colorectal Cancer Screening ClinicalTrials.gov
    blood sampling Other Approved Colorectal Cancer Screening ClinicalTrials.gov
    Weight Loss Intervention Other Phase PHASE3 Breast Carcinoma ClinicalTrials.gov
    Health Education Program Other Phase PHASE3 Breast Carcinoma ClinicalTrials.gov
    Peas supplement Other Approved Obesity ClinicalTrials.gov
    Kale supplement Other Approved Obesity ClinicalTrials.gov
    Survey using a questionnaire. Other Approved Screening for Colon Cancer ClinicalTrials.gov
    Quality of life questionnair Other Preclinical Incisional Hernia ClinicalTrials.gov
    Increase of physical activity volume and intensity with the use of a motivational smartphone application Other Approved Parkinson Disease ClinicalTrials.gov
    Placebo Other Phase PHASE3 Severe Asthma ClinicalTrials.gov
    Acarizax Other Phase PHASE3 Severe Asthma ClinicalTrials.gov
    Tezepelumab Other Phase PHASE3 Severe Asthma ClinicalTrials.gov
    C134 Other Phase PHASE1 Glioblastoma ClinicalTrials.gov
    MT-401 Other Phase PHASE2 Acute Myeloid Leukemia ClinicalTrials.gov
    Educational curriculum Other Approved Environmental Exposure ClinicalTrials.gov
    Urinary EDC metabolite testing Other Approved Environmental Exposure ClinicalTrials.gov
    MT-401-OTS Other Phase PHASE1 Acute Myeloid Leukemia, in Relapse ClinicalTrials.gov
    Blood Test and Report Back Other Approved Environmental Health Effects ClinicalTrials.gov
    Education curriculum Other Approved Environmental Exposure ClinicalTrials.gov
    Weight loss reporting Other Approved Obesity &Amp;Amp;Amp; Overweight ClinicalTrials.gov
    Siphox clinic biomarker test Other Approved Obesity &Amp;Amp;Amp; Overweight ClinicalTrials.gov
    Weight loss Application Other Approved Obesity &Amp;Amp;Amp; Overweight ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: MARKER THERAPEUTICS, INC.
    • Ticker Symbol: MRKR

Search

News categories